Syndrome & diagnostic formulation #
Describe delusions, hallucinations, thought disorganization, negative symptoms and behavioral change, with their duration and functional impact. Psychosis can occur in schizophrenia, mood episodes, medical illness and substance-related states; the first encounter may not establish the final longitudinal diagnosis.
Record the diagnostic system in use and the relationship between mood and psychotic episodes. Avoid prematurely labeling schizophrenia from an isolated hallucination, a PANSS total, or a brief intoxication-related presentation.
DSM schizophrenia requires a disturbance lasting at least 6 months, including an active phase of about 1 month (or shorter if successfully treated), functional decline and exclusion of mood, substance and medical explanations. Do not apply this DSM duration rule as if it were an ICD rule; state the classification explicitly.
First episode and relapse assessment #
Obtain the sequence of sleep disruption, behavioral change, mood symptoms, substance exposure and functional decline. Explore conviction, distress and associated actions without arguing about the belief. Seek collateral with appropriate consent and assess communication needs.
In established illness, compare the current state with baseline, recent adherence, formulation changes, substance use, physical illness and psychosocial stressors. Assess nutrition, self-neglect, self-harm, victimization and behavior requiring urgent support.
Differentials that change the pathway #
| Alternative | Clues / implication |
|---|---|
| Delirium | Fluctuating attention or awareness, abnormal vital signs or acute physical illness: investigate medically. |
| Mood disorder with psychosis | Establish whether psychosis occurs within mood episodes or independently. |
| Substances and medications | Cannabis, stimulants, withdrawal, corticosteroids and other exposures require an accurate temporal history. |
| Neurological or systemic illness | Atypical onset, seizures, focal signs or cognitive change broaden investigation and referral. |
Diagnostic tests and prescribing baseline #
| Context | What to assess | Why |
|---|---|---|
| Before antipsychotic treatment | Weight, waist, pulse/BP, glucose or HbA1c, lipids, prolactin and movement examination | Baseline adverse-effect comparison. |
| ECG | When required by product information, cardiovascular history/risk or inpatient admission | Assess cardiac vulnerability. |
| Possible secondary psychosis | Directed laboratory, toxicology or neurological investigation from history/examination | Investigate the suspected cause; no laboratory test confirms schizophrenia. |
Treatment sequence #
View treatment map
- First episode
Offer an oral antipsychotic with psychological and family interventions; begin at the lower licensed range and document the individual trial.
- Relapse
Reassess adherence, substance use and medical causes before switching; consider a long-acting formulation when preference or adherence makes it appropriate.
- Recovery
Provide family support, psychosocial rehabilitation and help with education, work and independent living.
- Persistent illness
Review trial adequacy and treatment resistance; address negative symptoms, cognitive burden and adverse effects separately.
| Situation | Management |
|---|---|
| First episode | Offer an oral antipsychotic with psychological and family interventions; begin at the lower licensed range and document the individual trial. |
| Relapse | Reassess adherence, substance use and medical causes before switching; consider a long-acting formulation when preference or adherence makes it appropriate. |
| Recovery | Provide family support, psychosocial rehabilitation and help with education, work and independent living. |
| Persistent illness | Review trial adequacy and treatment resistance; address negative symptoms, cognitive burden and adverse effects separately. |
Doses & prescribing #
Each prescribing record identifies its population and source jurisdiction; international labeling does not establish Indian approval. The clinician selects treatment after assessment.
Risperidone
Adult schizophrenia: selected oral label
Adults · Immediate-release tablets · Oral · United States product labeling
- Starting dose
- 2 mg/day, once or in divided doses.
- Titration
- Increase by 1–2 mg/day at intervals of at least 24 hours; slower titration may be appropriate.
- Treatment range / target
- Label target 4–8 mg/day; individualize to tolerability and response.
- Maximum / limits
- Label studied range extends to 16 mg/day. Doses above 6 mg/day with twice-daily dosing were not more efficacious and caused more EPS; this is not a routine high-dose target.
- Trial & duration
- Use an explicit adequate-dose trial and then reassess.
- Monitoring
- EPS, akathisia, prolactin symptoms, orthostasis and metabolic change.
- Population & organ-function adjustments
- Severe renal/hepatic impairment: start 0.5 mg twice daily; increases above 1.5 mg twice daily at intervals of at least 1 week.
- Important cautions
- Review CYP2D6 inhibitors, carbamazepine and cardiovascular risk; distinguish akathisia from agitation.
Aripiprazole
Adult schizophrenia
Adults · Immediate-release tablets · Oral · United States product labeling
- Starting dose
- 10–15 mg once daily.
- Titration
- Generally wait at least 2 weeks before increasing.
- Treatment range / target
- 10–15 mg/day is the recommended target; trials included up to 30 mg/day.
- Maximum / limits
- 30 mg/day; higher doses within the range were not more effective than 10–15 mg in the cited trials.
- Trial & duration
- Reassess symptoms and function after an adequate trial.
- Monitoring
- Akathisia, activation, impulsive/compulsive behaviors and metabolic parameters.
- Population & organ-function adjustments
- Known CYP2D6 poor metabolizer or strong CYP2D6/CYP3A4 inhibitor: usually half dose; combined strong inhibitors: quarter dose. Follow label for other combinations.
- Important cautions
- Do not mistake activating adverse effects for psychotic relapse. No approval for dementia-related psychosis.
Adequate trials & clozapine #
NICE recommends 4–6 weeks at an optimum antipsychotic dose for an explicit therapeutic trial. Review adherence and diagnostic alternatives before declaring failure.
Offer clozapine after inadequate response to two adequate antipsychotic trials, at least one a non-clozapine second-generation drug. Initiation requires its dedicated hematological, cardiovascular, bowel and other monitoring protocol; an ordinary antipsychotic dose table is insufficient.
Recovery and relapse prevention #
Continue a regimen that provides meaningful benefit while reassessing adverse effects and recovery goals. Discuss early warning signs, support contacts, missed-dose plans and practical barriers to treatment.
Withdrawal should be gradual and monitored for recurrence. Separate informed preference to reduce treatment from adverse effects, cost, access problems or beliefs about medication; each requires a different response.
Special populations & adverse-effect vulnerability #
Older adults and patients with orthostatic, renal or hepatic vulnerability may need lower starting exposure and slower titration. Do not extrapolate adult schizophrenia dosing to dementia-related behavioral symptoms.
Pregnancy, postpartum onset, intellectual disability and major physical illness require a tailored formulation and treatment discussion. Check formulation-specific restart and oral-overlap instructions before using long-acting preparations.
Follow-up domains #
| Domain | What to record |
|---|---|
| Clinical benefit | Target symptom change, functioning, sleep and the patient’s priorities; use the same scale when helpful. |
| Neurological effects | Akathisia, rigidity, tremor, dystonia and involuntary movements; examine rather than relying only on spontaneous reports. |
| Physical health | Weight trajectory, glucose/lipids, blood pressure, sexual/prolactin symptoms and medicine-specific cardiac concerns. |
| Recovery | Education/work, relationships, housing, substance use, engagement and practical access to treatment. |
Clinical pitfalls #
Do not increase an antipsychotic automatically for restlessness: akathisia may be the cause. Likewise, apparent negative symptoms may reflect depression, sedation, movement effects or social deprivation.
Discuss adverse effects that the person considers unacceptable before choosing treatment. A symptom score improvement with disabling adverse effects is not a successful overall outcome.
Assessment tools #
Choose the instrument for its intended purpose; interpretation accompanies the linked tool.
Patient discussion #
Open a plain-language explanation
Unusual experiences can be frightening. Understanding their timing and effects helps plan practical support and treatment together.
Further reading #
References · 7
- NICE CG178 — antipsychotic trials and treatment resistance · United Kingdom · Checked 2026-10-26 · Supports: Diagnostic tests and prescribing baseline; Treatment sequence; Adequate trials & clozapine; Recovery and relapse prevention
- NIMH — understanding psychosis · United States · Checked 2026-10-26 · Supports: Syndrome & diagnostic formulation; First episode and relapse assessment; Clinical pitfalls
- WHO — schizophrenia care and recovery · International · Checked 2026-10-26 · Supports: First episode and relapse assessment; Treatment sequence; Recovery and relapse prevention; Follow-up domains
- NHS — causes of psychosis · United Kingdom · Checked 2026-10-26 · Supports: Differentials that change the pathway; Diagnostic tests and prescribing baseline
- Risperidone tablets — product label, sections 2, 5 and 8 · United States · Checked 2026-10-26 · Supports: Special populations & adverse-effect vulnerability; Follow-up domains; Clinical pitfalls; Risperidone — Adult schizophrenia: selected oral label (Immediate-release tablets)
- Aripiprazole tablets — product label, sections 2, 5 and 8 · United States · Checked 2026-10-26 · Supports: Special populations & adverse-effect vulnerability; Follow-up domains; Clinical pitfalls; Aripiprazole — Adult schizophrenia (Immediate-release tablets)
- SAMHSA: DSM schizophrenia criteria comparison, Table 3.22 · United States; DSM framework · Checked 2026-10-26 · Supports: Syndrome & diagnostic formulation